Debiopharm Group

Debiopharm Group is a biopharmaceutical development specialist based in Lausanne, Switzerland, focusing on in-licensing promising biologics and small molecule drug candidates for global registration. The group aims to maximize the commercial potential of its products through out-licensing agreements with pharmaceutical partners for sales and marketing. It operates multiple investment arms, including the Debiopharm Innovation Fund, which invests in early-stage companies within the biotechnology, diagnostics, and digital health sectors, focusing on smart data and biomarker development. This fund typically invests between $1 million and $10 million, seeking minority stakes and board representation in its portfolio companies. Additionally, Debiopharm Investment engages in private equity and real estate investments, targeting mature companies in IT security and renewable sectors, as well as residential and commercial properties primarily in Western Europe. With a commitment to long-term investments and active involvement in corporate governance, Debiopharm Group drives its portfolio companies toward successful market exits.

Thierry Mauvernay

President and Delegate of the Board

Past deals in Switzerland

Coorpacademy

Series B in 2016
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and learning solutions tailored for employees. The company provides an innovative learning experience platform that offers a diverse catalog of training courses in the form of MOOCs. These courses consist of short sessions accessible at any time and on various devices, allowing users to engage with customized content that meets their specific learning needs. Coorpacademy aims to revolutionize digital learning by enhancing accessibility and personalization in employee training.

Coorpacademy

Series A in 2014
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and learning solutions tailored for employees. The company provides an innovative learning experience platform that offers a diverse catalog of training courses in the form of MOOCs. These courses consist of short sessions accessible at any time and on various devices, allowing users to engage with customized content that meets their specific learning needs. Coorpacademy aims to revolutionize digital learning by enhancing accessibility and personalization in employee training.

BPA Solutions

Funding Round in 2013
BPA Solutions SA is a global provider of innovative business applications and solutions that enhance Microsoft SharePoint and Office 365 environments. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a suite of regulatory software solutions that focus on quality management, risk management, and compliance with regulations such as GDPR. Their product offerings include BPA CRM, designed for frontline workforce management; BPA Quality for quality assurance; and BPA Risk for tracking business activities in complex environments. Additionally, BPA Solutions provides project management tools, recruitment solutions, and a Self-Service platform for process sharing with external communities. The company also offers a Solution Builder to facilitate the development of integrated components for enhanced user experiences. BPA Solutions serves clients through on-premise, private cloud, or hybrid environments and supports its offerings with professional services like training, installation, and project management. With operations in Switzerland, the United States, and India, BPA Solutions is positioned to support digital workplace initiatives globally.

Skioo

Venture Round in 2013
Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Compliant Concept

Venture Round in 2013
Compliant Concept AG is a Swiss company founded in 2009, specializing in the development of intelligent bed systems aimed at the treatment and prevention of pressure ulcers. Originating from a collaboration between the ETH Zurich and Empa, the company focuses on enhancing patient care in hospitals and nursing homes by providing innovative mobility monitors and risk management solutions. These systems not only assist in clinical risk assessments but also take into account various factors influencing patient care, such as medication and pre-bedtime activities. By automating routine tasks, Compliant Concept aims to reduce the workload for healthcare professionals, thereby improving overall care quality and creating a safer and more comfortable environment for patients.

Spinomix

Series A in 2013
Spinomix is a Swiss technology platform company based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), specializing in innovative sample processing solutions for the life sciences sector. The company aims to establish a new standard for the processing of biochemical substances, significantly enhancing the quality and efficiency of sample extraction and analysis. Spinomix focuses on critical applications that influence treatment decisions across various human diseases, as well as in animal health and food safety. Its flagship products, MagPhase™ and FibroTrap™, address the challenges posed by complex and heterogeneous samples such as blood, urine, and food matrices, improving both the accuracy and speed of diagnostic results. By leveraging advanced magnetic nanoparticles and microfluidics, Spinomix's automated systems promise to reduce labor intensity and streamline sample processing. The company targets high-growth markets, including nucleic acids extraction and molecular diagnostics, and is actively engaging in collaborations with industry players to validate its technologies and pursue strategic commercial partnerships.

Biocartis

Series D in 2012
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Skioo

Seed Round in 2012
Skioo is a company dedicated to enhancing the skiing experience by providing a seamless platform for ski ticketing and adventure booking. The Skioo Pass offers skiers instant access to an extensive network of partner resorts in Switzerland and beyond. By integrating with the systems of ski resorts, ski-lift operators, and online accommodation platforms, Skioo simplifies the booking process for users, allowing them to purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community of skiing enthusiasts and provides valuable information and features to enrich the skiing experience. Founded in 2019 as part of Skitude, Skioo is driven by a team of outdoor enthusiasts and collaborates with notable technology partners to deliver its services effectively.

Biocartis

Series C in 2011
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Biocartis

Series B in 2010
Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.